These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11016813)

  • 1. Putative roles of ouabainlike compound in hypertension: revisited.
    Goto A; Yamada K
    Hypertens Res; 2000 Sep; 23 Suppl():S7-13. PubMed ID: 11016813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ouabain-like factor.
    Goto A; Yamada K
    Curr Opin Nephrol Hypertens; 1998 Mar; 7(2):189-96. PubMed ID: 9529622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous ligand of alpha(1) sodium pump, marinobufagenin, is a novel mediator of sodium chloride--dependent hypertension.
    Fedorova OV; Talan MI; Agalakova NI; Lakatta EG; Bagrov AY
    Circulation; 2002 Mar; 105(9):1122-7. PubMed ID: 11877366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain sodium channels and central sodium-induced increases in brain ouabain-like compound and blood pressure.
    Wang H; Leenen FH
    J Hypertens; 2003 Aug; 21(8):1519-24. PubMed ID: 12872046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain sodium channels and ouabainlike compounds mediate central aldosterone-induced hypertension.
    Wang H; Huang BS; Leenen FH
    Am J Physiol Heart Circ Physiol; 2003 Dec; 285(6):H2516-23. PubMed ID: 12933342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous Na,K pump ligands are differentially regulated during acute NaCl loading of Dahl rats.
    Fedorova OV; Lakatta EG; Bagrov AY
    Circulation; 2000 Dec; 102(24):3009-14. PubMed ID: 11113054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Digoxin-like immunoreactivity: is it still worth measuring?
    Goto A; Yamada K; Yagi N; Hui C; Sugimoto T
    Life Sci; 1991; 49(23):1667-78. PubMed ID: 1658518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of human ouabainlike compound by micellar electrokinetic chromatography.
    Harwood S; Alfazema L; Perrett D; Dawnay A
    Hypertens Res; 2000 Sep; 23 Suppl():S29-32. PubMed ID: 11016816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of digoxin-specific antibody Fab fragment (Digibind) on blood pressure and renal water-sodium metabolism in 5/6 reduced renal mass hypertensive rats.
    Kaide J; Ura N; Torii T; Nakagawa M; Takada T; Shimamoto K
    Am J Hypertens; 1999 Jun; 12(6):611-9. PubMed ID: 10371371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digoxin antibody prevents cerebral hemorrhage-induced hypertension.
    Menezes JC; Dichtchekenian V
    Am J Hypertens; 2003 Dec; 16(12):1062-5. PubMed ID: 14643583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of NaCl and behavioral stress on endogenous sodium pump ligands in rats.
    Fedorova OV; Anderson DE; Lakatta EG; Bagrov AY
    Am J Physiol Regul Integr Comp Physiol; 2001 Jul; 281(1):R352-8. PubMed ID: 11404312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent progress on an endogenous digitalislike factor in hypertension.
    Cloix JF; Crabos M; Meyer P
    J Clin Hypertens; 1986 Jun; 2(2):93-100. PubMed ID: 3020179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Digoxin-like immunoreactivity, displacement of ouabain and inhibition of Na+/K+ ATPase by four steroids known to be increased in essential hypertension.
    Seccombe DW; Pudek MR; Nowaczynski W; Humphries KH
    Clin Biochem; 1989 Feb; 22(1):17-21. PubMed ID: 2539926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Endogenous digitalis-like factor].
    Yamazato M; Muratani H; Fukiyama K
    Nihon Rinsho; 1997 Aug; 55(8):1971-6. PubMed ID: 9284409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of sodium pump inhibitor induced vascular smooth muscle contraction with digibind. Stoichiometry and its implications.
    Krep HH; Graves SW; Price DA; Lazarus M; Ensign A; Soszynski PA; Hollenberg NK
    Am J Hypertens; 1996 Jan; 9(1):39-46. PubMed ID: 8834705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma ouabain-like factor during acute and chronic changes in sodium balance in essential hypertension.
    Manunta P; Messaggio E; Ballabeni C; Sciarrone MT; Lanzani C; Ferrandi M; Hamlyn JM; Cusi D; Galletti F; Bianchi G;
    Hypertension; 2001 Aug; 38(2):198-203. PubMed ID: 11509476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ouabainlike factor in Milan hypertensive rats.
    Ferrandi M; Minotti E; Salardi S; Florio M; Bianchi G; Ferrari P
    Am J Physiol; 1992 Oct; 263(4 Pt 2):F739-48. PubMed ID: 1329560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypotensive action of canrenone in a model of hypertension where ouabain-like factors are present.
    De Mendonca M; Grichois ML; Pernollet MG; Thorman B; Meyer P; Devynck MA; Garay R
    J Hypertens Suppl; 1985 Dec; 3(3):S73-5. PubMed ID: 2856827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous and exogenous cardiac glycosides and their mechanisms of action.
    Schoner W; Scheiner-Bobis G
    Am J Cardiovasc Drugs; 2007; 7(3):173-89. PubMed ID: 17610345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of Na-K-ATPase in human urine: effects of ouabain-like factors and of vanadium-diascorbate on calcium mobilization in rat vascular smooth muscle cells: comparison with the effects of ouabain, angiotensin II, and arginine-vasopressin.
    Meyer-Lehnert H; Bäcker A; Kramer HJ
    Am J Hypertens; 2000 Apr; 13(4 Pt 1):364-9. PubMed ID: 10821337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.